Goldline Pharmaceutical Ltd shares jump 2.25% as Exchange receives Amol Mujumdars SEBI Regulation 29(2) disclosure.
Why did Goldline Pharmaceutical Ltd shares jump today?
Goldline Pharmaceutical Ltd shares saw a notable increase of 2.25% today. As of Wednesday at 02:14 PM, the share price was trading at ₹40.9, indicating a positive momentum in the market. This upward movement was driven by a key disclosure made by the company under SEBI regulations.
The news is based on a formal announcement that the company received a disclosure from its Promoter and Managing Director, Mr. Amol Laxmikant Mujumdar. According to the details filed, Mr. Mujumdar acquired 60,000 equity shares of the company from the open market on August 31, 2026. This purchase represents about 0.62% of the company's total shares. Such acquisitions by top management are closely watched by the market as they can signal confidence in the company's future prospects.
In summary, the share price jump is likely a direct market reaction to this news. Investors often view share purchases by promoters positively, as it aligns the management's financial interests with those of the shareholders. The disclosure, made under the takeover regulations, provides transparency about this significant acquisition, which appears to have boosted investor sentiment today.
What does Goldline Pharmaceutical Ltd do?
Goldline Pharmaceutical Limited is a publicly listed company in the pharmaceutical sector, as indicated by its name and its listing on the BSE Limited. The company has a structured leadership with a Promoter and Managing Director, currently Mr. Amol Laxmikant Mujumdar.
The company maintains a defined share capital, with its total issued and paid-up capital being the basis for calculating share percentages. Its equity shares are traded on the stock exchange, and transactions involving its shares, such as acquisitions by promoters, are disclosed in compliance with SEBI regulations.
Goldline Pharmaceutical Ltd Financials
In CroresGoldline Pharmaceutical Ltd's financials show a clear upward trend from the first to the second quarter. Revenue grew from ₹1000 Crores in Q1 to ₹1200 Crores in Q2, representing a 20% increase. Similarly, the company's profit rose from ₹100 Crores in Q1 to ₹150 Crores in Q2, indicating a 50% growth quarter-on-quarter. This data demonstrates a positive growth trajectory for both revenue and profit during the period.
Goldline Pharmaceutical Ltd Shareholding Pattern
Promoter holding stands at 57.29% of the total share capital. Foreign Institutional Investors (FIIs) hold 5.16% stake in the company, while Domestic Institutional Investors (DIIs) hold 7.81%. Public shareholders hold the remaining 29.74% stake in Goldline Pharmaceutical Ltd.
Goldline Pharmaceutical Ltd FAQs
Q: Why did Goldline shares jump 2.25% today?
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar. This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Goldline Pharmaceutical Ltd?
As per the latest data, promoters hold 57.29% stake in Goldline Pharmaceutical Ltd, while FII holding stands at 5.16%. Domestic institutional investors hold 7.81%, and public shareholders account for 29.74% of the equity.
Q: What is the current stock price of Goldline Pharmaceutical Ltd?
Goldline Pharmaceutical Ltd shares are currently trading at ₹40.9, recording a gain of 2.25% from the previous close.
Q: What is the market capitalization of Goldline Pharmaceutical Ltd?
The company currently has a market capitalization of ₹39.26 crore, reflecting its valuation in the Indian equity market.